MedTrace Logo

Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00460265 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 658

Last updated 2014-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the treatment effect of Panitumumab in combination with chemotherapy versus chemotherapy alone as first line therapy for metastatic and/or recurrent squamous cell carcinoma of the head and neck.

Conditions

  • Recurrent and/or Metastatic Head and Neck Cancer

Interventions

DRUG

ARM 2

Subjects will receive Cisplatin plus 5FU

DRUG

ARM 1

Subjects will receive Panitumumab plus cisplatin and 5FU

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-05-31
Completion
2012-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00460265 on ClinicalTrials.gov